Nevro (NVRO) Expected to Announce Earnings on Wednesday

Nevro (NYSE:NVRO) is expected to release its earnings data before the market opens on Wednesday, February 19th. Analysts expect Nevro to post earnings of ($0.67) per share and revenue of $102.43 million for the quarter.

Nevro Stock Down 0.1 %

Shares of NVRO opened at $5.72 on Tuesday. Nevro has a 52 week low of $3.16 and a 52 week high of $17.63. The stock has a market capitalization of $214.14 million, a price-to-earnings ratio of -3.02 and a beta of 0.91. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.76 and a current ratio of 5.02. The stock has a fifty day moving average of $4.48 and a 200-day moving average of $4.98.

Analysts Set New Price Targets

Several research analysts recently issued reports on NVRO shares. Morgan Stanley lowered Nevro from an “equal weight” rating to an “underweight” rating and lowered their target price for the stock from $9.00 to $4.00 in a research report on Monday, December 2nd. Citigroup lowered their target price on Nevro from $6.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday, December 11th. Canaccord Genuity Group raised their target price on Nevro from $4.00 to $5.85 and gave the stock a “hold” rating in a research report on Friday, February 7th. Jefferies Financial Group upgraded Nevro from an “underperform” rating to a “hold” rating and increased their price target for the stock from $4.50 to $5.85 in a report on Monday, February 10th. Finally, Robert W. Baird increased their price target on Nevro from $5.00 to $6.00 and gave the stock a “neutral” rating in a report on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $6.43.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.